Technical Analysis for OPTN - OptiNose, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Historical OPTN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| BB Squeeze + Upper Band Touch | Range Contraction | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 3.35% | |
| Bollinger Band Squeeze | Range Contraction | 3.35% | |
| Bollinger Band Squeeze | Range Contraction | 5.71% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 5.71% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 15 hours ago |
| Rose Above Previous Day's High | about 16 hours ago |
| Rose Above Upper Bollinger Band | about 16 hours ago |
| Up 3% | about 16 hours ago |
| Up 2% | about 16 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/05/2020
OptiNose, Inc. is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other. The Company’s lead product, XHANCE (fluticasone propionate) nasal spray, utilizes breath powered exhalation delivery system (EDS), to deliver a topically acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. XHANCE has a differentiated clinical profile with the potential to become part of the standard of care for this disease because it is able to deliver medication to the primary site of inflammation
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Clinical Medicine Pharmaceutical Organ Systems Disease Inflammation Respiratory Therapy Polyp Allergy Icos Sinus Glucocorticoids Nasal Spray Corticosteroid Sinusitis Chronic Rhinosinusitis Fluticasone Nasal Polyps
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Clinical Medicine Pharmaceutical Organ Systems Disease Inflammation Respiratory Therapy Polyp Allergy Icos Sinus Glucocorticoids Nasal Spray Corticosteroid Sinusitis Chronic Rhinosinusitis Fluticasone Nasal Polyps
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.0 |
| 52 Week Low | 3.14 |
| Average Volume | 431,519 |
| 200-Day Moving Average | 4.27 |
| 50-Day Moving Average | 3.79 |
| 20-Day Moving Average | 3.55 |
| 10-Day Moving Average | 3.55 |
| Average True Range | 0.16 |
| ADX | 18.76 |
| +DI | 22.36 |
| -DI | 19.83 |
| Chandelier Exit (Long, 3 ATRs ) | 3.26 |
| Chandelier Exit (Short, 3 ATRs ) | 3.81 |
| Upper Bollinger Band | 3.69 |
| Lower Bollinger Band | 3.41 |
| Percent B (%b) | 1.05 |
| BandWidth | 7.68 |
| MACD Line | -0.05 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0291 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.96 | ||||
| Resistance 3 (R3) | 3.95 | 3.85 | 3.92 | ||
| Resistance 2 (R2) | 3.85 | 3.78 | 3.85 | 3.90 | |
| Resistance 1 (R1) | 3.77 | 3.74 | 3.81 | 3.79 | 3.89 |
| Pivot Point | 3.67 | 3.67 | 3.69 | 3.68 | 3.67 |
| Support 1 (S1) | 3.60 | 3.61 | 3.64 | 3.61 | 3.51 |
| Support 2 (S2) | 3.50 | 3.57 | 3.51 | 3.50 | |
| Support 3 (S3) | 3.43 | 3.50 | 3.48 | ||
| Support 4 (S4) | 3.44 |
